Search company, investor...

Predict your next investment

Oxford Science Enterprises company logo
Venture Capital
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing / Management & Strategy Consulting
oxfordscienceenterprises.com

See what CB Insights has to offer

Investments

112

Portfolio Exits

7

Funds

1

Partners & Customers

8

Service Providers

1

About Oxford Science Enterprises

Oxford Science Enterprises is an independent investment company created to found, fund and build sciences businesses through its partnership with the University of Oxford. The company was founded in 2015 and is based in Oxford, England.

Headquarters Location

46 Woodstock Road

Oxford, England, OX2 6HT,

United Kingdom

+44 01865 950 000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Oxford Science Enterprises Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxford Science Enterprises Rank

Latest Oxford Science Enterprises News

T-Cypher Bio separates from Orbit Discovery to build a

Nov 1, 2022

pipeline of TCR therapeutics for solid tumours and other indications Company has potential to unlock an expansive therapeutic target space by decoding natural T-cell responses in both oncology and autoimmune diseases. Closed financing led by Oxford Sciences Innovation with participation from RT Ventures, Borealis Ventures, University of Oxford, and a private investor Oxford, UK, 25 February 2021 – T-Cypher Bio (‘T-Cypher’, or ‘the Company’), a rapidly emerging private biotech company pioneering a novel approach to TCR therapeutics has launched today. Established in late 2020, T-Cypher has separated from Orbit Discovery (“Orbit”) to focus on developing a functional, high-throughput, bead-display platform to select therapeutically relevant targets and identify potent, target-specific TCRs for the treatment of solid tumours and other indications. The formation of T-Cypher has been financed by Oxford Sciences Innovation (“OSI”) with participation from RT Ventures, Borealis Ventures, the University of Oxford, and a private investor. All investors were original Orbit investors. Over the past nine months, OSI has worked closely with co-founder, Graham Ogg and the Orbit team to aid in the formation of T-Cypher adding an experienced management team and leading advisers. T-Cypher will use its proprietary bead-display microfluidic platform to investigate a broad target landscape identified through bespoke immunopeptidomics. The company will focus on identifying targets within new antigen classes that have not been explored with existing technologies. Its functional high-throughput approach allows the company to interrogate TCR-specificity without the need for laborious T cell cloning or soluble-TCR generation and will allow for the identification of a broad-range of therapeutically relevant antigen:TCR pairs. Commenting on the development, Professor Graham Ogg, Co-founder and SAB Chair of T-Cypher and Professor of Dermatology at the University of Oxford, and Past Director of the MRC Human Immunology Unit, WIMM, said: "T-Cypher has the leading technology in the field for deconvoluting vast T cell repertoires, enabling development of the adaptive immune therapeutics of the future. Its innovative bead-based microfluidic platform enables high-throughput functionality testing of T cells directly from patients. I’m excited to be supporting the team in building an end-to-end business to establish a pipeline of TCR based products.” Commenting on the formation of T-Cypher, Uciane Scarlett, PhD, Interim Executive Chair & OSI Investment Principal, said: “Working hand-in-hand with Graham we have built a specialised team that is aligned with the Company’s ambitious goals. Research within Orbit over the past few years allows T-Cypher to hit the ground running and immediately begin work to generate new TCR therapies in both oncology and non-oncology. We are delighted to work closely with T-Cypher in its formation and beyond. We’re very confident in the company’s future growth.” Commenting on the challenges and benefits of T-Cypher, Dr Luke Williams, Interim Head of Research and Development, and OSI Scientist-in-Residence said: “T-Cypher’s approach overcomes many of the challenges that other companies have faced when selecting therapeutically relevant targets for immunotherapies. Our ability to identify a broad range of potential targets and use our platform to interrogate immune responses in patients of interest, will be a significant step forward in this rapidly growing sector. I’m excited to be working with such a strong team to develop the next generation of TCR-based treatments.” The company will remain in stealth as it focuses on building out its platform and pipeline. - Ends - About T-Cypher Bio T-Cypher Bio, a rapidly emerging biotechnology company headquartered in Oxford, UK, is pioneering a novel approach to develop next generation TCR therapeutics and utilise state of the art techniques to identify a broad-range of potential targets, for both solid tumours and other indications. These techniques offer a vast library of candidate antigen peptides for recognition by T cells and the ability to test T cell functionality directly from patients without the need for T cell cloning, TCR generation or immortalised T cells. Through harnessing the knowledge gained within Orbit Discovery, the Company is building a pipeline of game-changing treatments for patients, with the potential to save lives. For more information please visit: https://tcypherbio.com/ About OSI Oxford Sciences Innovation is a leading science and technology business. OSI ensures Oxford’s world-leading science moves out of the laboratory and onto the global stage. In partnership with the University of Oxford, OSI creates fundamental technology companies, built on science. We match scientists with experienced entrepreneurs and patient capital to turn idea to impact, discovery to company. OSI invests in Life Sciences, Deep Tech, Healthtech, AI and Software to create companies taking on challenges like diagnosis and treatment of disease and cancer, hyper resolution microscopy, renewable energy, drones, nuclear fusion and quantum computing. Founded in 2015, we’ve raised over $800M of evergreen capital, building on Oxford’s renowned research legacy, to create a leading science and technology ecosystem and home for entrepreneurs. OSI backs companies from their inception and invest for the long-term, helping them to build their businesses by finding senior management talent, entrepreneurs, expert advisors and global investors to realise their vision. OSI reinvests any returns back into the Oxford ecosystem and the next generation of scientists and technologies to create even more companies capable of tackling more of the world’s most important problems. About RT Ventures Founded in 2016 RT Ventures is a leading investor in UK University spin-out companies, with a focus on life science and healthcare technology. About Borealis Venture Borealis Ventures is an early-stage venture capital firm partnering closely with exceptional entrepreneurs since 2002 to build visionary healthcare companies. Borealis focuses on life science platforms, digital health, and animal health opportunities, often involving the translation of university-based innovation. For more information, please visit: www. borealis.vc . About The University of Oxford The University of Oxford has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions. Through its research commercialisation arm, Oxford University Innovation, Oxford is the leading university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years.

Oxford Science Enterprises Investments

112 Investments

Oxford Science Enterprises has made 112 investments. Their latest investment was in Osler as part of their Series C on November 11, 2022.

CBI Logo

Oxford Science Enterprises Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/7/2022

Series C

Osler

$85M

No

9

11/3/2022

Seed VC - II

Util

$6M

No

6

10/19/2022

Series A

Nucleome Therapeutics

$42.22M

Yes

18

7/21/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/9/2022

Series A

Subscribe to see more

Subscribe to see more

10

Date

11/7/2022

11/3/2022

10/19/2022

7/21/2022

7/9/2022

Round

Series C

Seed VC - II

Series A

Series A

Series A

Company

Osler

Util

Nucleome Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$85M

$6M

$42.22M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

9

6

18

10

10

Oxford Science Enterprises Portfolio Exits

7 Portfolio Exits

Oxford Science Enterprises has 7 portfolio exits. Their latest portfolio exit was MiroBio on August 04, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/4/2022

Acquired

$99M

8

7/22/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/30/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/27/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/16/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/4/2022

7/22/2021

4/30/2021

10/27/2020

4/16/2020

Exit

Acquired

Acquired

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

8

10

10

10

10

Oxford Science Enterprises Fund History

1 Fund History

Oxford Science Enterprises has 1 fund, including Oxford Sciences Innovation.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/9/2016

Oxford Sciences Innovation

$729.46M

4

Closing Date

12/9/2016

Fund

Oxford Sciences Innovation

Fund Type

Status

Amount

$729.46M

Sources

4

Oxford Science Enterprises Partners & Customers

8 Partners and customers

Oxford Science Enterprises has 8 strategic partners and customers. Oxford Science Enterprises recently partnered with Lothbury Investment Management on March 3, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

3/14/2022

Partner

United Kingdom

Oxford Science Enterprises enters agreement with Lothbury to develop state-of-the-art R&D facilities in Oxford City Centre – Oxford Science Enterprises

Oxford Science Enterprises , the Science Business Builder and preferred investment partner of the University of Oxford , announces it has entered into a joint venture with the Lothbury Property Trust to develop high-specification laboratory and office space , for early-stage life science businesses , in the heart of Oxford Science Enterprises city centre .

1

11/4/2020

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

1/11/2018

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

12/11/2017

Partner

Germany

Subscribe to see more

Subscribe to see more

10

12/11/2017

Partner

United Kingdom, and Germany

Subscribe to see more

Subscribe to see more

10

Date

3/14/2022

11/4/2020

1/11/2018

12/11/2017

12/11/2017

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United Kingdom

United Kingdom

United Kingdom

Germany

United Kingdom, and Germany

News Snippet

Oxford Science Enterprises enters agreement with Lothbury to develop state-of-the-art R&D facilities in Oxford City Centre – Oxford Science Enterprises

Oxford Science Enterprises , the Science Business Builder and preferred investment partner of the University of Oxford , announces it has entered into a joint venture with the Lothbury Property Trust to develop high-specification laboratory and office space , for early-stage life science businesses , in the heart of Oxford Science Enterprises city centre .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Oxford Science Enterprises Service Providers

1 Service Provider

Oxford Science Enterprises has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Investment Bank

Bookrunner

Service Provider

Associated Rounds

Provider Type

Investment Bank

Service Type

Bookrunner

Partnership data by VentureSource

Oxford Science Enterprises Team

6 Team Members

Oxford Science Enterprises has 6 team members, including current Chief Executive Officer, Alexis Dormandy.

Name

Work History

Title

Status

Alexis Dormandy

RED, Orange, Virgin Group, and McKinsey & Company

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Alexis Dormandy

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

RED, Orange, Virgin Group, and McKinsey & Company

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.